Jacek Gronwald

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4140145/publications.pdf

Version: 2024-02-01

301 papers	22,897 citations	15880 67 h-index	11946 139 g-index
313 all docs	313 docs citations	313 times ranked	23317 citing authors

#	Article	IF	Citations
1	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
2	Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2022, 164, 514-521.	0.6	8
3	An Assessment of GPX1 (rs1050450), DIO2 (rs225014) and SEPP1 (rs7579) Gene Polymorphisms in Women with Endometrial Cancer. Genes, 2022, 13, 188.	1.0	5
4	Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp>CD8⁺ TIL</scp> infiltration, and provides no independent prognostic value in endometriosisâ€associated ovarian carcinomas. Journal of Pathology, 2022, 256, 388-401.	2.1	15
5	Risk of Second Primary Thyroid Cancer in Women with Breast Cancer. Cancers, 2022, 14, 957.	1.7	5
6	An Assessment of Serum Selenium Concentration in Women with Endometrial Cancer. Nutrients, 2022, 14, 958.	1.7	2
7	Spectrum and frequency of CHEK2 variants in breast cancer affected and general population in the Baltic states region, initial results and literature review. European Journal of Medical Genetics, 2022, 65, 104477.	0.7	5
8	Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor. Hereditary Cancer in Clinical Practice, 2022, 20, 11.	0.6	4
9	The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations. British Journal of Cancer, 2022, 127, 84-91.	2.9	4
10	Frequency of BRCA1 and BRCA2 mutations in ovarian cancer patients in South-East Poland. Hereditary Cancer in Clinical Practice, 2022, 20, 12.	0.6	0
11	Common Variant in ALDH2 Modifies the Risk of Breast Cancer Among Carriers of the p.K3326* Variant in BRCA2. JCO Precision Oncology, 2022, 6, e2100450.	1.5	1
12	Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1351-1358.	1.1	3
13	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	1.1	12
14	Population-based targeted sequencing of 54 candidate genes identifiesPALB2as a susceptibility gene for high-grade serous ovarian cancer. Journal of Medical Genetics, 2021, 58, 305-313.	1.5	26
15	Lung Cancer Occurrenceâ€"Correlation with Serum Chromium Levels and Genotypes. Biological Trace Element Research, 2021, 199, 1228-1236.	1.9	13
16	Blood cadmium levels as a marker for early lung cancer detection. Journal of Trace Elements in Medicine and Biology, 2021, 64, 126682.	1.5	28
17	Prevalence of germline TP53 variants among early-onset breast cancer patients from Polish population. Breast Cancer, 2021, 28, 226-235.	1.3	10
18	Breast cancer risk after age 60 amongÂBRCA1 andÂBRCA2 mutation carriers. Breast Cancer Research and Treatment, 2021, 187, 515-523.	1.1	5

#	Article	IF	Citations
19	Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer. Cancers, 2021, 13, 849.	1.7	13
20	Survival from breast cancer in women with a BRCA2 mutation by treatment. British Journal of Cancer, 2021, 124, 1524-1532.	2.9	12
21	Serum Selenium Level Predicts 10-Year Survival after Breast Cancer. Nutrients, 2021, 13, 953.	1.7	14
22	PALB2 mutations and prostate cancer risk and survival. British Journal of Cancer, 2021, 125, 569-575.	2.9	18
23	Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers. Cancers, 2021, 13, 3345.	1.7	6
24	Serum Selenium Level and 10-Year Survival after Melanoma. Biomedicines, 2021, 9, 991.	1.4	8
25	Low Blood-As Levels and Selected Genotypes Appears to Be Promising Biomarkers for Occurrence of Colorectal Cancer in Women. Biomedicines, 2021, 9, 1105.	1.4	0
26	Genetic predisposition to male breast cancer in Poland. BMC Cancer, 2021, 21, 975.	1.1	7
27	Influence of the Levels of Arsenic, Cadmium, Mercury and Lead on Overall Survival in Lung Cancer. Biomolecules, 2021, 11, 1160.	1.8	23
28	BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update. Hereditary Cancer in Clinical Practice, 2021, 19, 13.	0.6	8
29	Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?. Cancers, 2021, 13, 5464.	1.7	1
30	Blood Copper Levels and the Occurrence of Colorectal Cancer in Poland. Biomedicines, 2021, 9, 1628.	1.4	19
31	Blood arsenic levels and the risk of familial breast cancer in Poland. International Journal of Cancer, 2020, 146, 2721-2727.	2.3	18
32	BRCA1 promoter methylation in peripheral blood is associated with the risk of tripleâ€negative breast cancer. International Journal of Cancer, 2020, 146, 1293-1298.	2.3	33
33	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
34	Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?. Menopause, 2020, 27, 156-161.	0.8	5
35	Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2020, 159, 820-826.	0.6	10
36	Polymorphisms in MMP-1, MMP-2, MMP-7, MMP-13 and MT2A do not contribute to breast, lung and colon cancer risk in polish population. Hereditary Cancer in Clinical Practice, 2020, 18, 16.	0.6	14

#	Article	IF	Citations
37	Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland. Cancers, 2020, 12, 2321.	1.7	11
38	Mutations in ATM , NBN and BRCA2 predispose to aggressive prostate cancer in Poland. International Journal of Cancer, 2020, 147, 2793-2800.	2.3	27
39	CA125 and Ovarian Cancer: A Comprehensive Review. Cancers, 2020, 12, 3730.	1.7	174
40	Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers. International Journal of Gynecological Cancer, 2020, 30, 825-830.	1.2	4
41	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	9.4	265
42	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	3.2	43
43	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. British Journal of Cancer, 2020, 123, 793-802.	2.9	35
44	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. Journal of the National Cancer Institute, 2020, 112, 1242-1250.	3.0	106
45	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	0.6	32
46	Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers. Menopause, 2020, 27, 1396-1402.	0.8	8
47	Evaluation of the constructed device along with the software for digital archiving, sending the data, and supporting the diagnosis of cervical cancer.. Journal of Clinical Oncology, 2020, 38, e18017-e18017.	0.8	0
48	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.4	49
49	Influence of the selenium level on overall survival in lung cancer. Journal of Trace Elements in Medicine and Biology, 2019, 56, 46-51.	1.5	25
50	Allelic modification of breast cancer risk in women with an NBN mutation. Breast Cancer Research and Treatment, 2019, 178, 427-431.	1.1	6
51	Inherited Variants in BLM and the Risk and Clinical Characteristics of Breast Cancer. Cancers, 2019, 11, 1548.	1.7	11
52	Inherited variants in XRCC2 and the risk of breast cancer. Breast Cancer Research and Treatment, 2019, 178, 657-663.	1.1	13
53	A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy. Gynecologic Oncology, 2019, 155, 270-274.	0.6	15
54	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88

#	Article	IF	Citations
55	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Modern Pathology, 2019, 32, 1834-1846.	2.9	54
56	The spectrum of mutations predisposing to familial breast cancer in Poland. International Journal of Cancer, 2019, 145, 3311-3320.	2.3	39
57	BARD1 is a Low/Moderate Breast Cancer Risk Gene: Evidence Based on an Association Study of the Central European p.Q564X Recurrent Mutation. Cancers, 2019, 11, 740.	1.7	25
58	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	5.8	90
59	Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy. Hereditary Cancer in Clinical Practice, 2019, 17, 10.	0.6	1
60	Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2019, 175, 443-449.	1.1	12
61	Serum selenium level and cancer risk: a nested case-control study. Hereditary Cancer in Clinical Practice, 2019, 17, 33.	0.6	15
62	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	2.6	711
63	Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers. Breast Cancer Research and Treatment, 2019, 174, 769-774.	1.1	7
64	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	3.0	30
65	Inherited NBN Mutations and Prostate Cancer Risk and Survival. Cancer Research and Treatment, 2019, 51, 1180-1187.	1.3	21
66	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic Proceedings, 2018, 93, 307-320.	1.4	22
67	Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. JAMA Oncology, 2018, 4, 1059.	3.4	121
68	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	2.9	15
69	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
70	Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2018, 169, 561-571.	1.1	25
71	Predictors of survival for breast cancer patients with a BRCA1 mutation. Breast Cancer Research and Treatment, 2018, 168, 513-521.	1.1	20
72	The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer, 2018, 142, 2263-2272.	2.3	20

#	Article	IF	Citations
73	Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland. Hereditary Cancer in Clinical Practice, 2018, 16, 6.	0.6	12
74	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2018, 47, 450-459.	0.9	15
75	Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. International Journal of Epidemiology, 2018, 47, 987-997.	0.9	11
76	Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2018, 150, 85-91.	0.6	65
77	Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2018, 171, 421-426.	1.1	10
78	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology: Clinical Research, 2018, 4, 250-261.	1.3	70
79	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.4	54
80	Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population. PLoS ONE, 2018, 13, e0201065.	1.1	30
81	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	1.1	9
82	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	1.8	3
83	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535.	2.9	23
84	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
85	Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?. Gynecologic Oncology, 2017, 145, 346-351.	0.6	33
86	Dose-Response Association of CD8⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 2017, 3, e173290.	3.4	260
87	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	13.7	1,099
88	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
89	Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer. Hereditary Cancer in Clinical Practice, 2017, 15, 4.	0.6	17
90	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18

#	Article	IF	Citations
91	Bilateral Oophorectomy and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	3.0	160
92	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 420-424.	1.1	3
93	The impact of an expanded genetic testing program and selective oophorectomy on the incidence of ovarian cancer in West Pomerania. Clinical Genetics, 2017, 91, 322-327.	1.0	3
94	Body mass index and breast cancer survival: a Mendelian randomization analysis. International Journal of Epidemiology, 2017, 46, 1814-1822.	0.9	45
95	The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome. Cancer Research and Treatment, 2017, 49, 430-436.	1.3	19
96	Evaluation of Microfluidics-FISH method in prenatal diagnosis. Ginekologia Polska, 2017, 88, 670-673.	0.3	3
97	PARS PLANA VITRECTOMY IN ADVANCED CASES OF VON HIPPELâ€“LINDAU EYE DISEASE. Retina, 2016, 36, 325-334.	1.0	21
98	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	0.9	71
99	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Human Molecular Genetics, 2016, 25, 3600-3612.	1.4	17
100	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	1.5	174
101	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	1.8	19
102	The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients. Breast Cancer Research and Treatment, 2016, 156, 371-378.	1.1	13
103	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	0.9	111
104	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	7.7	157
105	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	2.2	42
106	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5.8	93
107	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
108	Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers. Journal of Ovarian Research, 2016, 9, 11.	1.3	10

#	Article	IF	Citations
109	Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a caseâ€“control study. Breast Cancer Research and Treatment, 2016, 155, 365-373.	1.1	55
110	Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertility and Sterility, 2016, 105, 781-785.	0.5	38
111	The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study. British Journal of Cancer, 2016, 114, 1160-1164.	2.9	24
112	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
113	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 446-454.	1.1	9
114	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	3.0	77
115	Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility, 2016, 105, 35-43.e10.	0.5	37
116	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
117	Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction. PLoS ONE, 2016, 11, e0153844.	1.1	17
118	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	0.8	5
119	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	0.8	13
120	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	0.6	22
121	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
122	Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 2015, 17, 58.	2.2	26
123	Recurrent mutations of <scp>BRCA1</scp> and <scp>BRCA2</scp> in Poland: an update. Clinical Genetics, 2015, 87, 288-292.	1.0	35
124	Review Selenium as aÂmarker of cancer risk and of selection for control examinations in surveillance. Wspolczesna Onkologia, 2015, 1A, 60-61.	0.7	4
125	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	1.1	44
126	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221

#	Article	IF	Citations
127	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	3.2	33
128	Germline RECQL mutations are associated with breast cancer susceptibility. Nature Genetics, 2015, 47, 643-646.	9.4	168
129	Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. Familial Cancer, 2015, 14, 383-391.	0.9	28
130	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	0.6	15
131	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
132	Management of ovarian and endometrial cancers in women belonging to HNPCC carrier families: review of the literature and results of cancer risk assessment in Polish HNPCC families. Hereditary Cancer in Clinical Practice, 2015, 13, 3.	0.6	11
133	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. Molecular Cancer Therapeutics, 2015, 14, 1495-1503.	1.9	26
134	Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncology, The, 2015, 16, 638-644.	5.1	137
135	The variant allele of the rs188140481 polymorphism confers a moderate increase in the risk of prostate cancer in Polish men. European Journal of Cancer Prevention, 2015, 24, 122-127.	0.6	5
136	Common variants at theCHEK2gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	1.3	24
137	Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?. Breast Cancer Research and Treatment, 2015, 154, 163-169.	1.1	6
138	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	1.4	68
139	Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. Journal of Clinical Oncology, 2015, 33, 2901-2907.	0.8	266
140	Weight Gain After Oophorectomy Among Women with a BRCA1 or BRCA2 Mutation. Women's Health, 2015, 11, 453-459.	0.7	2
141	Factors influencing ovulation and the risk of ovarian cancer in <scp>BRCA1</scp> and <scp>BRCA2</scp> mutation carriers. International Journal of Cancer, 2015, 137, 1136-1146.	2.3	56
142	Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern Europe. Familial Cancer, 2015, 14, 145-149.	0.9	12
143	Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland. Clinical Genetics, 2015, 88, 366-370.	1.0	34
144	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	1.1	22

#	Article	IF	Citations
145	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
146	Abstract POSTER-CTRL-1213: Whole exome and targeted resequencing, of population based ovarian cancer cases and controls, identifies susceptibility genes for ovarian cancer. , 2015, , .		0
147	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	1.5	47
148	Variation in NF-ÎºB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427.	1.1	13
149	Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	2.2	97
150	Risk of Ovarian Cancer and the NF-ÎºB Pathway: Genetic Association with IL1A and TNFSF10. Cancer Research, 2014, 74, 852-861.	0.4	48
151	Large-Scale Evaluation of Common Variation in Regulatory T Cellâ€“Related Genes and Ovarian Cancer Outcome. Cancer Immunology Research, 2014, 2, 332-340.	1.6	21
152	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	2.2	57
153	The presence of prostate cancer at biopsy is predicted by a number of genetic variants. International Journal of Cancer, 2014, 134, 1139-1146.	2.3	6
154	Survival from breast cancer in patients with CHEK2 mutations. Breast Cancer Research and Treatment, 2014, 144, 397-403.	1.1	12
155	Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Research and Treatment, 2014, 143, 579-586.	1.1	68
156	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics, 2014, 133, 481-497.	1.8	23
157	Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. British Journal of Cancer, 2014, 110, 530-534.	2.9	120
158	Lynch syndrome mutations shared by the Baltic States and Poland. Clinical Genetics, 2014, 86, 190-193.	1.0	5
159	Consortium analysis of gene and geneâ€“folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 2014, 58, 2023-2035.	1.5	16
160	First recurrent large genomic rearrangement in the BRCA1 gene found in Poland. Cancer Epidemiology, 2014, 38, 382-385.	0.8	1
161	Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study. Breast Cancer Research and Treatment, 2014, 147, 113-118.	1.1	24
162	Large deletion causing von Hippel-Lindau disease and hereditary breast cancer syndrome. Hereditary Cancer in Clinical Practice, 2014, 12, 16.	0.6	5

#	Article	IF	Citations
163	Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Research and Treatment, 2014, 147, 401-405.	1.1	224
164	Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2014, 146, 421-427.	1.1	35
165	BRCA1 founder mutations compared to ovarian cancer in Belarus. Familial Cancer, 2014, 13, 445-447.	0.9	6
166	Association of common WRAP 53 variant with ovarian cancer risk in the Polish population. Molecular Biology Reports, 2013, 40, 2145-2147.	1.0	16
167	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	9.4	326
168	The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland. Prostate, 2013, 73, 542-548.	1.2	31
169	A common nonsense mutation of the BLM gene and prostate cancer risk and survival. Gene, 2013, 532, 173-176.	1.0	24
170	Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families. Molecular Biology Reports, 2013, 40, 6619-6623.	1.0	15
171	Ten-Year Survival in Patients With BRCA1-Negative and BRCA1-Positive Breast Cancer. Journal of Clinical Oncology, 2013, 31, 3191-3196.	0.8	112
172	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
173	Clinical characteristics of breast cancer in patients with an NBS1 mutation. Breast Cancer Research and Treatment, 2013, 141, 471-476.	1.1	3
174	The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: An international prospective cohort study. Gynecologic Oncology, 2013, 130, 127-131.	0.6	106
175	Are Two-Centimeter Breast Cancers Large or Small?. Current Oncology, 2013, 20, 205-211.	0.9	9
176	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	1.5	244
177	Optimizing recruitment to a prostate cancer surveillance program among male BRCA1 mutation carriers: invitation by mail or by telephone. Hereditary Cancer in Clinical Practice, 2013, 11, 17.	0.6	2
178	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	5.8	144
179	An inherited NBN mutation is associated with poor prognosis prostate cancer. British Journal of Cancer, 2013, 108, 461-468.	2.9	89
180	A personalised approach to prostate cancer screening based on genotyping of risk founder alleles. British Journal of Cancer, 2013, 108, 2601-2609.	2.9	16

#	Article	IF	Citations
181	Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 987-992.	1.1	20
182	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	5.8	98
183	A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370.	1.1	23
184	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	1.1	47
185	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Research, 2012, 14, R110.	2.2	179
186	The risk of breast cancer in women with a BRCA1 mutation from North America and Poland. International Journal of Cancer, 2012, 131, 229-234.	2.3	38
187	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. British Journal of Cancer, 2012, 106, 2016-2024.	2.9	27
188	Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study. Cancer Causes and Control, 2012, 23, 1065-1074.	0.8	26
189	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	1.1	34
190	Selenium as marker for cancer risk and prevention. Polski Przeglad Chirurgiczny, 2012, 84, 470-5.	0.2	3
191	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 2011, 103, 250-263.	3.0	596
192	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2011, 20, 3289-3303.	1.4	152
193	On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. European Journal of Human Genetics, 2011, 19, 300-306.	1.4	107
194	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. International Journal of Cancer, 2011, 128, 2063-2074.	2.3	54
195	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	1.4	68
196	Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Human Molecular Genetics, 2011, 20, 2263-2272.	1.4	22
197	Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer. Journal of Clinical Oncology, 2011, 29, 3747-3752.	0.8	207
198	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116.	3.0	40

#	Article	IF	Citations
199	Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium. PLoS ONE, 2011, 6, e20703.	1.1	21
200	BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Research and Treatment, 2010, 119, 201-211.	1.1	70
201	BRCA1 mutations and colorectal cancer in Poland. Familial Cancer, 2010, 9, 541-544.	0.9	33
202	Variant alleles of the CYP1B1 gene are associated with colorectal cancer susceptibility. BMC Cancer, 2010, 10, 420.	1.1	28
203	Alcohol consumption and the risk of breast cancer among BRCA1 and BRCA2 mutation carriers. Breast, 2010, 19, 479-483.	0.9	24
204	CHEK2 mutations and HNPCCâ€•related colorectal cancer. International Journal of Cancer, 2010, 126, 3005-3009.	2.3	28
205	Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics, 2010, 42, 880-884.	9.4	235
206	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics, 2010, 42, 874-879.	9.4	321
207	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	9.4	309
208	The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania. Clinical Genetics, 2010, 78, 373-376.	1.0	28
209	The contribution of founder mutations in BRCA1 to breast cancer in Belarus. Clinical Genetics, 2010, 78, 377-380.	1.0	22
210	Family History of Cancer and Cancer Risks in Women with BRCA1 or BRCA2 Mutations. Journal of the National Cancer Institute, 2010, 102, 1874-1878.	3.0	89
211	Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. Journal of Medical Genetics, 2010, 47, 99-102.	1.5	61
212	Combined iPLEX and TaqMan Assays to Screen for 45 Common Mutations in Lynch Syndrome and FAP Patients. Journal of Molecular Diagnostics, 2010, 12, 82-90.	1.2	8
213	Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy. Journal of Clinical Oncology, 2010, 28, 375-379.	0.8	500
214	Vitamin D receptor variants and breast cancer risk in the Polish population. Breast Cancer Research and Treatment, 2009, 115, 629-633.	1.1	27
215	Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Research and Treatment, 2009, 115, 359-363.	1.1	299
216	Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk. Breast Cancer Research and Treatment, 2009, 117, 161-165.	1.1	22

#	Article	IF	Citations
217	Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology. Breast Cancer Research and Treatment, 2009, 114, 121-126.	1.1	13
218	The 4154delA mutation carriers in the BRCA1 gene share a common ancestry. Familial Cancer, 2009, 8, 1-4.	0.9	7
219	Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations. Familial Cancer, 2009, 8, 473-478.	0.9	6
220	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nature Genetics, 2009, 41, 996-1000.	9.4	276
221	Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband. British Journal of Cancer, 2009, 100, 1508-1512.	2.9	37
222	Estrogen receptor status in CHEK2â€positive breast cancers: implications for chemoprevention. Clinical Genetics, 2009, 75, 72-78.	1.0	53
223	Haplotype of the C61GBRCA1Mutation in Polish and Jewish Individuals. Genetic Testing and Molecular Biomarkers, 2009, 13, 465-469.	0.3	13
224	Identification of Patients at High Risk of Psychological Distress After BRCA1 Genetic Testing. Genetic Testing and Molecular Biomarkers, 2009, 13, 325-330.	0.3	21
225	Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Research and Treatment, 2008, 108, 289-296.	1.1	136
226	A six-nucleotide deletion in the CASP8 promoter is not associated with a susceptibility to breast and prostate cancers in the Polish population. Breast Cancer Research and Treatment, 2008, 112, 367-368.	1.1	18
227	Early radiation exposures and BRCA1-associated breast cancer in young women from Poland. Breast Cancer Research and Treatment, 2008, 112, 581-584.	1.1	33
228	Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a caseâ€“control study. Cancer Causes and Control, 2008, 19, 1111-1119.	0.8	87
229	International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer, 2008, 122, 2017-2022.	2.3	306
230	Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations. Journal of Medical Genetics, 2008, 46, 132-135.	1.5	25
231	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. British Journal of Cancer, 2008, 98, 1457-1466.	2.9	461
232	Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism. BMC Cancer, 2008, 8, 90.	1.1	5
233	The VEGF_936_C>T 3â€²UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. Cancer Letters, 2008, 262, 71-76.	3.2	46
234	Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. Carcinogenesis, 2008, 29, 762-765.	1.3	41

#	Article	IF	Citations
235	Predictors of Contralateral Prophylactic Mastectomy in Women With a BRCA1 or BRCA2 Mutation: The Hereditary Breast Cancer Clinical Study Group. Journal of Clinical Oncology, 2008, 26, 1093-1097.	0.8	161
236	A Range of Cancers Is Associated with the rs6983267 Marker on Chromosome 8. Cancer Research, 2008, 68, 9982-9986.	0.4	111
237	Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers. Journal of the National Cancer Institute, 2008, 100, 1361-1367.	3.0	179
238	Hereditary breast and ovarian cancer. Hereditary Cancer in Clinical Practice, 2008, 6, 88.	0.6	7
239	BRCA1 mutations and prostate cancer in Poland. European Journal of Cancer Prevention, 2008, 17, 62-66.	0.6	33
240	Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland. European Journal of Cancer Prevention, 2008, 17, 389-391.	0.6	13
241	Integrin Â3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk. Journal of Medical Genetics, 2007, 44, 408-411.	1.5	11
242	AURKAF31I Polymorphism and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1416-1421.	1.1	30
243	The RAD51 135 G>C Polymorphism Modifies Breast Cancer and Ovarian Cancer Risk in Polish BRCA1 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 270-275.	1.1	59
244	Phenocopies in breast cancer 1 (BRCA1) families: implications for genetic counselling. Journal of Medical Genetics, 2007, 44, e76-e76.	1.5	25
245	Epistatic Relationship between the Cancer Susceptibility Genes CHEK2 and p27. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 572-576.	1.1	21
246	Selected aspects of genetic counselling for BRCA1 mutation carriers. Hereditary Cancer in Clinical Practice, 2007, 5, 3.	0.6	0
247	RAD51 135Gâ†'C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. American Journal of Human Genetics, 2007, 81, 1186-1200.	2.6	217
248	Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?. European Journal of Human Genetics, 2007, 15, 237-241.	1.4	61
249	A survey of preventive measures among BRCA1 mutation carriers from Poland. Clinical Genetics, 2007, 71, 153-157.	1.0	12
250	A deletion in CHEK2 of 5,395Âbp predisposes to breast cancer in Poland. Breast Cancer Research and Treatment, 2007, 102, 119-122.	1.1	102
251	CDKN2A-positive breast cancers in young women from Poland. Breast Cancer Research and Treatment, 2007, 103, 355-359.	1.1	22
252	The 3â€² untranslated region CÂ>ÂT polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation. Breast Cancer Research and Treatment, 2007, 104, 67-74.	1.1	15

#	Article	IF	Citations
253	Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. Breast Cancer Research and Treatment, 2007, 104, 299-308.	1.1	47
254	CYP1B1 and predisposition to breast cancer in Poland. Breast Cancer Research and Treatment, 2007, 106, 383-388.	1.1	18
255	BARD1 and breast cancer in Poland. Breast Cancer Research and Treatment, 2007, 107, 119-122.	1.1	26
256	A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. Journal of Medical Genetics, 2006, 43, 863-866.	1.5	103
257	Coverage of the Genetic Background of Breast Cancer in the Polish Population. Hereditary Cancer in Clinical Practice, 2006, 4, 25.	0.6	0
258	Low-risk Genes and Multi-organ Cancer Risk in the Polish Population. Hereditary Cancer in Clinical Practice, 2006, 4, 52.	0.6	1
259	Population Screening for Cancer Family Syndromes in the West Pomeranian Region of Poland. Hereditary Cancer in Clinical Practice, 2006, 4, 56.	0.6	7
260	Population Screening of CHEK2 Mutations in Poland. Hereditary Cancer in Clinical Practice, 2006, 4, 57.	0.6	2
261	A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet. Hereditary Cancer in Clinical Practice, 2006, 4, 58.	0.6	4
262	Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Research and Treatment, 2006, 95, 105-109.	1.1	82
263	Prevalence of the NOD2 3020insC mutation in aggregations of breast and lung cancer. Breast Cancer Research and Treatment, 2006, 95, 141-145.	1.1	31
264	Male to female ratio among offspring of BRCA1 mutation carriers. Breast Cancer Research and Treatment, 2006, 97, 113-114.	1.1	2
265	XPD Common Variants and their Association with Melanoma and Breast Cancer Risk. Breast Cancer Research and Treatment, 2006, 98, 209-215.	1.1	47
266	BRCA1-positive breast cancers in young women from Poland. Breast Cancer Research and Treatment, 2006, 99, 71-76.	1.1	40
267	Direct-to-patient BRCA1 testing: the Twoj Styl experience. Breast Cancer Research and Treatment, 2006, 100, 239-245.	1.1	31
268	Tamoxifen and contralateral breast cancer inBRCA1 andBRCA2 carriers: An update. International Journal of Cancer, 2006, 118, 2281-2284.	2.3	246
269	CHEK2-Positive Breast Cancers in Young Polish Women. Clinical Cancer Research, 2006, 12, 4832-4835.	3.2	32
270	The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs. Hereditary Cancer in Clinical Practice, 2005, 3, 59.	0.6	26

#	Article	IF	Citations
271	NOD2 variants and the risk of malignant melanoma. European Journal of Cancer Prevention, 2005, 14, 143-146.	0.6	16
272	Germline MSH2 and MLH1 mutational spectrum including large rearrangements in HNPCC families from Poland (update study). Clinical Genetics, 2005, 69, 40-47.	1.0	34
273	Comparison of genomic abnormalities between BRCAX and sporadic breast cancers studied by comparative genomic hybridization. International Journal of Cancer, 2005, 114, 230-236.	2.3	32
274	The 3020insC allele of NOD2 predisposes to early-onset breast cancer. Breast Cancer Research and Treatment, 2005, 89, 91-93.	1.1	47
275	Pathology of breast cancer in women with constitutional CHEK2 mutations. Breast Cancer Research and Treatment, 2005, 90, 187-189.	1.1	39
276	Breast cancer predisposing alleles in Poland. Breast Cancer Research and Treatment, 2005, 92, 19-24.	1.1	110
277	High Incidence of 4153delA BRCA1 Gene Mutations in Lithuanian Breast- and Breast-ovarian Cancer Families. Breast Cancer Research and Treatment, 2005, 94, 111-113.	1.1	21
278	A common variant of CDKN2A (p16) predisposes to breast cancer. Journal of Medical Genetics, 2005, 42, 763-765.	1.5	70
279	Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. Journal of Medical Genetics, 2005, 42, 602-603.	1.5	121
280	Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status. Journal of Medical Genetics, 2005, 43, 424-428.	1.5	19
281	Transmission of mutant alleles to female offspring of BRCA1 carriers in Poland. Journal of Medical Genetics, 2005, 42, e40-e40.	1.5	1
282	CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Research, 2005, 65, 835-9.	0.4	43
283	A protein truncating BRCA1 allele with a low penetrance of breast cancer. Journal of Medical Genetics, 2004, 41, e130-e130.	1.5	11
284	A high proportion of founderBRCA1mutations in Polish breast cancer families. International Journal of Cancer, 2004, 110, 683-686.	2.3	170
285	CHEK2 Is a Multiorgan Cancer Susceptibility Gene. American Journal of Human Genetics, 2004, 75, 1131-1135.	2.6	426
286	Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutations. Journal of Applied Genetics, 2004, 45, 255-63.	1.0	5
287	Hereditary ovarian cancer in Poland. International Journal of Cancer, 2003, 106, 942-945.	2.3	82
288	A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer. European Journal of Human Genetics, 2003, 11, 955-958.	1.4	34

#	Article	IF	Citations
289	Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. American Journal of Human Genetics, 2003, 72, 1117-1130.	2.6	3,105
290	Non-random transmission of mutant alleles to female offspring of BRCA1 carriers in Poland. Journal of Medical Genetics, 2003, 40, 719-720.	1.5	8
291	Clinical characteristics of hereditary ovarian cancer (HOC) in Poland. Ginekologia Polska, 2002, 73, 733-9.	0.3	0
292	Characterization of a familial RCC-associated t(2;3)(q33;q21) chromosome translocation. Journal of Human Genetics, 2001, 46, 685-693.	1.1	25
293	Founder mutations in the BRCA1 gene in west Belarusian breast-ovarian cancer families. Clinical Genetics, 2001, 60, 470-471.	1.0	26
294	Detection of germline mutations in the BRCA1 gene by RNA-based sequencing. Human Mutation, 2001, 18, 149-156.	1.1	21
295	Founder Mutations in the BRCA1 Gene in Polish Families with Breast-Ovarian Cancer. American Journal of Human Genetics, 2000, 66, 1963-1968.	2.6	222
296	Molecular Analyses in Diagnosis of High Genetic Predispositions to Malignancies.. Journal of Clinical Biochemistry and Nutrition, 2000, 28, 159-165.	0.6	0
297	Clinical Genetic Services for Familial Breast Cancer in Poland. Disease Markers, 1999, 15, 46-46.	0.6	1
298	Loss or reduction of Fhit expression in renal neoplasias: Correlation with histogenic class. Human Pathology, 1999, 30, 1276-1283.	1.1	18
299	Chromosomal abnormalities in renal cell neoplasms associated with acquired renal cystic disease. A series studied by comparative genomic hybridization and fluorescence in situ hybridization. , 1999, 187, 308.		2
300	Molecular Evidence for Derivation of Metastatic Cells from Minor Subclones of Primary Clear Renal Cell Carcinomas. Cancer Detection and Prevention, 1999, 23, 479-484.	2.1	7
301	Translocation (X;1)(p11.2;q21) in a Papillary Renal Cell Carcinoma in a 14-Year-Old Girl. Cancer Genetics and Cytogenetics, 1998, 101, 159-161.	1.0	21